| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | -0.007 | 0.8 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | methylstat | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | UNC1215 | GDSC1000 | pan-cancer | AAC | -0.0062 | 0.9 |